{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:46:56Z","timestamp":1790012816548,"version":"4.0.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2025.2604457","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T16:06:24Z","timestamp":1767456384000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care"],"prefix":"10.1080","volume":"29","author":[{"given":"Hans C.","family":"Lee","sequence":"first","affiliation":[{"name":"Myeloma Research, Sarah Cannon Research Institute","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey","family":"Yang","sequence":"additional","affiliation":[{"name":"Consulting, Analysis Group, Inc.","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Real-World Value & Evidence, Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[{"name":"Consulting, Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Consulting, Analysis Group, Inc.","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Goble","sequence":"additional","affiliation":[{"name":"Value & Evidence Scientific Engagement, Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Patel","sequence":"additional","affiliation":[{"name":"Value & Scientific Evidence Engagement, Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinke","family":"Zhang","sequence":"additional","affiliation":[{"name":"Real-World Evidence & Advanced Analytics, Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffit Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00853-3"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.002"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4137"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00431-5"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361035"},{"key":"e_1_3_5_12_1","unstructured":"TALVEY (talquetamab-tgvs) injection for subcutaneous use [package. inset]. Available from https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf."},{"key":"e_1_3_5_13_1","volume-title":"Am Soc Clin Oncol (ASCO)","author":"Rasche L","year":"2025","unstructured":"Rasche L, Schinke CD, Touzeau C, et al. 7528 Efficacy and safety from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D3CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analyses at an extended median follow-up. Am Soc Clin Oncol (ASCO); May 30\u2013June 3, 2025; Chicago, IL, USA; 2025."},{"issue":"4","key":"e_1_3_5_14_1","first-page":"1","article-title":"AMCP format for formulary submissions 5.0","volume":"30","year":"2024","unstructured":"AMCP format for formulary submissions 5.0. J Manage Care Special Pharm. 2024;30(4\u2013b)Suppl):1\u201364.","journal-title":"J Manage Care Special Pharm"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.00234.x"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2514909"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408892"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_3_5_19_1","volume-title":"European Hematology Association (EHA) Congress","author":"Mateos MV","year":"2025","unstructured":"Mateos MV, Jakubowiak A, Einsele H, et al. PS1736. Talquetamab vs real-world physician\u2019s choice in patients with relapsed\/refractory multiple myeloma and prior B-cell maturation antigen therapy: updated analyses of Monumental-1 vs LocoMMotion\/MoMMent. European Hematology Association (EHA) Congress; June 12\u201315, 2025; Milan, Italy ; 2025."},{"key":"e_1_3_5_20_1","unstructured":"J&J. Data on file. Clinical study report of MonumenTAL-1; 2024."},{"key":"e_1_3_5_21_1","unstructured":"J&J. Data on file. A prospective noninterventional multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. (LocoMMotion- dc Oct 2022); 2024."},{"key":"e_1_3_5_22_1","unstructured":"IBM Corporation. Micromedex RED BOOK 2025. [cited 2025 February 26]. Available from: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178896"},{"key":"e_1_3_5_24_1","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index (CPI) Medical Care Component. 2025 [cited 2025 Feb 28]. Available from: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM."},{"key":"e_1_3_5_25_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule; 2025 [cited 2025 Feb 28]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_5_26_1","unstructured":"Centers for Medicare & Medicaid Services. Clinical Diagnostic Laboratory Fee Schedule: CY 2025 Q1 Release; 2025 [cited 2025 Feb 28]. Available from: https:\/\/www.cms.gov\/license\/ama?file=\/files\/zip\/25clabq1.zip."},{"key":"e_1_3_5_27_1","unstructured":"National Institute for Health and Care Excellence. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib [TA338]; 2015 [cited 2024 Aug 23]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta338."},{"key":"e_1_3_5_28_1","unstructured":"KYPROLIS (carfilzomib) for injection for intravenous use [package inset]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/202714s034lbl.pdf."},{"key":"e_1_3_5_29_1","unstructured":"POMALYST (pomalidomide) capsules for oral use [package inset]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204026s031lbl.pdf."},{"key":"e_1_3_5_30_1","unstructured":"EMPLICITI (elotuzumab) for injection for intravenous use [package inset]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761035s015lbl.pdf."},{"key":"e_1_3_5_31_1","unstructured":"NINLARO (ixazomib) capsules for oral use [package inset]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208462s017lbl.pdf."},{"key":"e_1_3_5_32_1","unstructured":"DARZALEX (daratumumab) injection for intravenous use [package inset]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761036s044lbl.pdf."},{"key":"e_1_3_5_33_1","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUPnet). 2025 [cited 2025 April 3]. Available from: https:\/\/hcupnet.ahrq.gov\/."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1194278"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00198-0"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2020.0023"},{"key":"e_1_3_5_37_1","unstructured":"Lopez E Neuman T Jacobson G et al. How Much More Than Medicare Do Private Insurers Pay? A Review of the Literature: Washington D.C: Kaiser Family Foundation. 2020 [cited 2024 Nov 26]. Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/comparing-private-payer-and-medicare-payment-rates-for-select-inpatient-hospital-services\/."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"e_1_3_5_39_1","doi-asserted-by":"crossref","unstructured":"Chari A Touzeau C Schinke C et al. Talquetamab a G Protein-Coupled Receptor Family C Group 5 Member D\u2009\u00d7\u2009CD3 Bispecific Antibody in Patients With Relapsed\/Refractory Multiple Myeloma: Phase 1\/2 Results From MonumenTAL-1 (Poster). Presented at the 64th American Society of Hematology (ASH) Annual Meeting; December 10\u201313 2022; New Orleans LA USA. ; 2022 [cited 2024 Feb 24]. Available from: http:\/\/www.congresshub.com\/Oncology\/ASH2022\/Talquetamab\/Chari.","DOI":"10.1182\/blood-2022-159707"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.58"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282490"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8036"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1648802"},{"key":"e_1_3_5_49_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma V.2.2025. \u00a9 National Comprehensive Cancer Network Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way. [cited June 17 2025]."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01980-3"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S501404"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1779064"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2144056"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2604457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T16:06:25Z","timestamp":1767456385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2604457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2604457"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2604457","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}